EE347 Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure in Panama

Heart Failure (HF) is a high-cost chronic disease with frequent worsening events requiring expensive hospital treatments. This study evaluated the cost-utility of dapagliflozin in patients HF Panama. A Markov model was developed considering three states: HF, and death. The base case an ejection fraction 40% or less New York Association class II, III, IV symptoms. Perspective from third payer; comparators are no treatment. Outcomes death expressed Quality Adjusted Life Years (QALYs). There two-time horizons, 12 24 months, based on efficacy pivotal clinical trial HF. Costs were estimated advisory board cardiologists Willingness-to-Pay (WTP) used times gross domestic product per capita (USD 36,807). At months follow-up, strategy costs $ 933 generates 0.938 QALYs, without treatment, cost 706 0.923 QALYs. 1,763 1.74 it 1,130 1.70 Incremental Cost-Effectiveness Ratio (ICER) at 15,276, 13,373 additional QALY gained. Willingness-to-pay curves estimate that probability best treatment 61.3 %, 63.3 %. Dapagliflozin cost-effective for treating treatments much lower who receive than do not it.